A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive study treatment, and complete scheduled assessments of disease activity, symptoms, quality of life, safety, pharmacokinetics, and biomarker responses.

NCT Number	NCT07643766
Lead Sponsor	Enveda Therapeutics
Conditions	Atopic Dermatitis
Enrollment	200 participants
Start Date	2026-06-29
Primary Completion	2027-12 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-06